Onceyearly zoledronic acid for treatment of postmenopausal osteoporosis article in obstetrical and gynecological survey 628. It is also approved to increase bone mass in men with osteoporosis and for the prevention of new clinical fractures in patients who have recently had a lowtrauma hip fracture. Zoledronic acid is approved for the prevention and treatment of osteoporosis in postmenopausal women. Effect of intravenous zoledronic acid on tibiofemoral.
Onceyearly zoledronic acid for treatment of postmenopausal osteoporosis. Osteoporosis op is defined as a skeletal disorder characterized by decreased bone strength, which predisposes to an increase in fracture risk. The following information is not intended to endorse any particular medication. In the us, zoledronic acid zoledronic acid systemic is a member of the drug class bisphosphonates and is used to treat hypercalcemia of malignancy, osteolytic bone lesions of multiple myeloma, osteolytic bone metastases of solid tumors, osteoporosis, pagets disease and prevention of osteoporosis. Acido zoledronico aclasta indicacion clinica solicitada. It is also indicated for the treatment of pagets disease of the bone. Acido zoledronico solucion inyectable 4 mg5 ml eurofarma. Zometa apresentacoes 4 mg100 ml via intravenosa uso adulto. Zometa zoledronic acid dose, indications, adverse effects.
Zoledronic acid aclasta is an injectable bisphosphonate drug. Pdf acido zolendronico en osteoporosis alberto rodriguez. It is indicated for the treatment of osteoporosis in postmenopausal women. Importance a proofofprinciple study suggested that intravenous zoledronic acid may reduce knee pain and the size of bone marrow lesions in people with knee osteoarthritis, but data from large trials are lacking objective to determine the effects of intravenous zoledronic acid on knee cartilage volume loss in patients with symptomatic knee osteoarthritis and bone marrow lesions. Common side effects include fever, joint pain, high blood pressure, diarrhea, and.
Osteoporosis, bisfosfonatos, alendronato, risedronato, ibandronato, acido zoledronico, denosumab. Zoledronic acid aclasta for osteoporosis nps medicinewise. Reclast, a thirdgeneration nitrogencontaining bisphosphonate, is the first onceyearly treatment to have been approved for use in patients with postmenopausal osteoporosis or at high risk of fracture. Zoledronic acid is a potent intravenous bisphosphonate. Osteonecrosis related to onceyearly zoledronic acid. Zoledronic acid, also known as zoledronate, is a medication used to treat a number of bone diseases. Onceyearly zoledronic acid for treatment of postmenopausal. The 0 to 24 hour renal clearance of zoledronic acid was 3. Highlights of prescribing information adequately rehydrate. Affected cytochrome p450 isoenzymes and drug transporters.
Recomendaciones ser sobre osteoporosis ser sociedad. Zoledronic acid is indicated for the prevention of skeletalrelated events sres such as pathological fractures, bone pain, spinal compression, need for bone radiation, or surgery in patients with bone metastases, at a recommended dose of 4 mg iv every 34 weeks, and for the treatment of hypercalcemia of malignancy hcm at a recommended dose. Acido zoledronico 5 mg por osteoporosis en mujeres posmenopausicas. To prepare reduced doses for patients with baseline crcl less than or equal to 60 mlmin, withdraw the. These alterations change the microarchitecture of bone, reducing its quality and making it more susceptible to fracture.
Identificacion del farmaco y autores del informe farmaco. A 2year randomized, multicenter, doubleblind, placebocontrolled study to determine the efficacy and safety of intravenous zoledronic acid 5 mg administered either annually at randomization and 12 months, or administered at randomization only in the prevention. Postmenopausal osteoporosis is often treated with bisphosphonates bp. Concerning it use with cancer patients, the company says that zometa is the only bisphosphonate effective and approved in preventing sres in multiple tumor types, including breast cancer, prostate cancer, lung cancer, multiple myeloma and other solid tumor types. Zoledronic acid clearance was independent of dose but dependent upon the patients creatinine clearance.
Black dm1, delmas pd, eastell r, reid ir, boonen s, cauley ja, cosman f, lakatos p, leung pc, man z, mautalen c, mesenbrink p, hu h, caminis j, tong k, rosariojansen t, krasnow j, hue tf, sellmeyer d, eriksen ef, cummings sr. Zoledronic acid 4 mg usually infused every 34 weeks is used to treat hypercalcaemia and to prevent skeletalrelated events in people with malignancies. The study reported that after receiving three years of treatment, patients who received zoledronic acid aclasta experienced. These fractures are associated with increased morbidity and mortality. Zoledronic acid reclast national osteoporosis foundation. Osteoporosis, diphosphonates, pharmacoepidemiology source. None zoledronic acid does not inhibit any cyp450 enzymes in vitro. Zometa osteoporosis information who makes this drug. Zometa is manufactured by novartis, one of the worlds largest drug companies. It is given by injection into a vein common side effects include fever, joint pain, high blood pressure, diarrhea, and feeling tired. This solution is readytouse and may be administered directly to the patient without further preparation.
357 916 842 465 642 390 684 969 1022 919 721 821 1006 67 228 724 1227 72 971 710 553 221 731 89 1389 21 612 267 1054 981 1285